Alembic Pharmaceutical touches 52-week high, gets fresh USFDA approval

Pratik Shastri
/ Categories: Trending, DSIJ News
Alembic Pharmaceutical touches 52-week high, gets fresh USFDA approval

On Tuesday, Alembic Pharmaceutical declared that it has received USFDA approval for its Deferasirox tablets, leading to its shares trading high on BSE.

Deferasirox tablets are indicated in cases when the patient has an overload of iron in the body. These are often prescribed to blood cancer as well as thalacemia patients. According to the company filing on stock exchanges, the drug also has a part in treatment of chronic iron overload in non-transfusion-dependent thalassemia syndromes which is also part of iron overload issue in human body.

On the work front, after final approvals for Deferasirox tablets, 90 mg and 360 mg, have been received by the company, it is now working on getting approval for 180 mg strength as a third category of these drugs.

Including the latest ANDA approval, the company has a total of 122 ANDA approvals, of which 109 are at the final stage and 13 have been granted tentative approvals by US regulator.

The IQVIA, a US-based company, which is engaged in serving as the information and database provider of the healthcare industry, stated that Deferasirox Tablets, 180 mg, has an estimated market size of US$ 53 million (Rs 400 crore approximately).

Post the recent rally, the share price of Alembic Pharmaceuticals has touched a 52-week high of Rs 943 intraday on BSE. On Tuesday, shares were trading at Rs 927.55, higher by 4 per cent.

Rate this article:
5.0

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2024

Mindshare29-Mar, 2024

Multibaggers28-Mar, 2024

Interviews28-Mar, 2024

Multibaggers28-Mar, 2024

Knowledge

General26-Mar, 2024

MF25-Mar, 2024

General18-Mar, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR